Navigation Links
Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast cancer
Date:5/28/2009

ORLANDO (June 1, 2009)Fox Chase Cancer Center researchers report that a combination of trastuzumab and neratinib (HKI-272) a novel small molecule inhibitor of the HER2 receptor (ErbB2) appears active in women with HER2-positive metastatic breast cancer who have progressed on previous trastuzumab based therapies. More than one-quarter of the women in a phase I/II trial had their tumors shrink on the combination therapy.

"I think this is very promising. Neratinib induces clinically meaningful responses," says Ramona Swaby, M.D., a medical oncologist and attending physician at Fox Chase. Swaby will present the study results on Monday, June 1, at the annual meeting of the American Society of Clinical Oncology.

Trastuzumab is standard therapy for women with HER2-positive metastatic breast cancer and the majority of women respond to the treatment. However, over time some women will develop resistance to the drug and their tumors will start to grow again. For these women, alternative therapies are needed.

Both trastuzumab and neratinib inhibit the HER2 receptor expressed on the surface of HER2-positive breast cancer cells. Trastuzumab blocks the extracellular portion of the receptor, while neratinib blocks the intracellular portion. Researchers think that the combination may provide the one-two punch necessary to knock out the tumor cells.

Forty-five women with trastuzumab-resistant breast cancer enrolled in the trial. In the phase I portion of the trial, women received either 160 mg or 240 mg neratinib daily plus trastuzumab 4 mg/kg IV loading dose followed by 2 mg/kg weekly. None of the patients experienced dose limiting toxicities. The most common grade 3/4 adverse events included diarrhea (13%), nausea (4%) and vomiting (4%). The researchers saw no evidence of cardiac toxicity with the combination.

Of the 33 patients in the phase II portion of the trial who are evaluable for response, nine (27%) had an objective response to the combination therapy. Additionally, 47% were progression-free at 16 weeks, which was the primary endpoint of the trail, and the median progression-free survival was 19 weeks. Seven women continue on therapy at this time. (Updated results will be presented at the meeting.)

"Trastuzumab has certainly made a difference in patient care, but there is still room for improvement," Swaby says. "For example because trastuzumab is an antibody it does not cross the blood-brain barrier so is not effective at treating or preventing brain metastases. It is incredibly heartbreaking to think you are out of the woods and then to have brain metastases occur. Neratinib, a small molecule drug that can cross the blood-brain barrier, potentially may treat brain metastases. More studies are needed"

"The phase II data are snapshots of what this drug is capable of," Swaby says. "Phase III trials are underway, which I think is the right next step for this medicine. My patients in the study did well."


'/>"/>

Contact: Frank Hoke
Franklin.Hoke@fccc.edu
215-475-2888
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Lingraphica introduces the SmallTalk mobile accessory for aphasia
2. National Small Business Week Update: Sam's Club Announces Simplified Small Business Membership; Partnership With U.S. Chamber of Commerce, Plus Free One-Day Pass
3. Indias Non-Small-Cell Lung Cancer Drug Market Will Almost Double by 2013
4. Scientists discover how smallpox may derail human immune system
5. Make No Small Plans: M. D. Anderson Cancer Center Endeavors to Make Cancer History
6. Veterans Administration Awards Small Business' $13 Million Contract to Digitize Veterans Health Records
7. Cardinal Health to Offer Allscripts Electronic Health Record to Solo and Small Physician Groups
8. Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
9. BlueChoice HealthPlan Adds Coverage for Young Adults and New Plans for Small Businesses
10. Exercise programs may improve symptoms in non-small cell lung cancer patients
11. Scope of Swine Flu Outbreak in Mexico Might Be Smaller Than Thought
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh has posted a ... Yisrayl says this generation is a time like no other and society needs to understand ... Yisrayl says he does not want to sound like an old bible beater because religion ...
(Date:1/20/2017)... ... ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality nutritional supplements for ... Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures its entire line ... all clients at reasonable prices. At the ECRM trade show, it had a unique ...
(Date:1/20/2017)... Boca Raton, FL (PRWEB) , ... January 20, 2017 , ... ... highest level of nutritional and bodybuilding supplements, announced it attended the January ECRM trade ... a respected bodybuilder and nutritional scientist who was determined to create a line of ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has launched ... The drinks have been produced in collaboration with Zlatan Ibrahimovic and have been ... , After a successful launch in Sweden last year, the next generation sports ...
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account ... Word: Chocolate Biscuit” is the creation of published author, Marlyn Ivey, born in Lynn Haven, ... he went to school and at 19 years of age, he joined the Navy and ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017 Many patients don,t realize that they ... a pharmacy just a few blocks away charges only ... problem Medicationdiscountcard.com has created a price comparison ... much their medication will cost at most nearby pharmacies. ... Medicationdiscountcard.com takes all of the ...
(Date:1/19/2017)... , January 19, 2017 Incretin Mimetics/GLP-1 Agonists, ... Others The global anti-obesity drugs market is ... half of the forecast period and CAGR of 38.7% in the ... grow at a CAGR of 32.8% from 2016 to 2027. The ... 2021, and $24,063 million in 2027. ...
(Date:1/19/2017)... -- Accuray Incorporated (Nasdaq: ARAY ) announced ... set the bar for excellence in customer satisfaction. The ... rating among radiation treatment delivery systems in the U.S., ... Briefing™. The most recent ratings trend also shows Accuray ... for 11 of the past 12 quarters. ...
Breaking Medicine Technology: